Skip to main content
WELLBIOTEC CO.,LTD logo

WELLBIOTEC CO.,LTD — Investor Relations & Filings

Ticker · 010600 ISIN · KR7010600005 KO Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2022-06-21 Capital/Financing Update
Country KR South Korea
Listing KO 010600

About WELLBIOTEC CO.,LTD

http://www.wellbiotec.com/?language=eng

WELLBIOTEC CO.,LTD. is a diversified company with operations in several sectors. Its business activities include the development and distribution of biopharmaceutical products, such as specialized medicines, health functional foods, and diagnostic kits. The company is also involved in the electric vehicle (EV) charging business and logistics. Additionally, it manufactures and sells leather products for fashion goods, including shoes and handbags.

Recent filings

Filing Released Lang Actions
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the issuance of convertible bonds (전환사채권 발행결정). This type of regulatory filing in the Korean market is used to disclose significant corporate events, such as capital raising through debt instruments. Since it details the specific terms, purpose, and board resolution of a financing activity, it falls under the 'Capital/Financing Update' category.
2022-06-21 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding the issuance of convertible bonds (전환사채권 발행결정) and specifically details a correction (정정신고) to the terms of the issuance, such as maturity dates, payment dates, and conversion periods. This falls under capital structure and financing updates. According to the provided definitions, documents related to fundraising, financing activities, or capital structure changes are classified as CAP.
2022-05-27 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal disclosure regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) between Wellbiotech and Japan MEDIX HOLDING Co., Ltd. It details the contract value, duration, and nature of the goods (BTS lenticular products). Since this is a specific regulatory disclosure of a material business contract that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2022-05-17 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document tracks changes in significant share ownership (5% rule) and is categorized as a Major Shareholding Notification.
2022-05-13 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Wellbiotec Co., Ltd. for the period ending March 31, 2022. It contains detailed financial information, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-12 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity's shareholding in a listed company crosses certain thresholds. This specific document details the changes in shareholding by Sangsangin Savings Bank in Well Biotech Co., Ltd. due to convertible bond conversions and subsequent market sales. This falls under the 'Major Shareholding Notification' category.
2022-05-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.